Meet Gynecologic Surgeon Dennis Chi
Dennis S. Chi, MD, FACOG, FACS
Ronald O. Perelman Chair in Gynecologic Surgery; Deputy Chief, Gynecology Service; Head, Ovarian Cancer Surgery, Department of Surgery
Gynecologic Oncology; Cervical Cancer; Uterine Cancer; Ovarian Cancer
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Chi accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, New York University
Obstetrics and Gynecology - New York University School of Medicine
Gynecologic Oncology - Memorial Sloan Kettering Cancer Center
Obstetrics and Gynecology; Gynecologic Oncology
I have been an attending surgeon at Memorial Sloan Kettering Cancer Center for more than 25 years. I have devoted my career to caring for women with cancerous and noncancerous gynecologic diseases, including cervical cancer, uterine cancer, and ovarian/fallopian tube cancer. I have served as Deputy Chief of the Gynecology Service since 2010 and Head of the Ovarian Cancer Surgery Section since 2014. In 2021, I partnered with colleagues in the Departments of Medicine and Nursing as well as the Clinical Genetics Service to start the Comprehensive Assessment and Treatment of Cancers with Hereditary predisposition (CATCH) program. As the Surgical Director of this program, it is my goal to ensure that patients and family members who are at an increased risk for developing inherited cancers can be enrolled in a cutting-edge program, staffed by expert medical professionals, who can help them navigate the maze of consultations, screening tests, and preventive measures that are needed once this type of diagnosis is made.
My mother was an OB-GYN, so I entered my residency believing that I would take over her practice. This changed during my first year of training, when I cared for patients with gynecologic cancers and learned about the procedures used to treat these diseases. I saw how quality of care and surgery were so essential to positive outcomes for these patients, and that inspired me to go into the gynecologic oncology subspecialty. I wanted to develop an expertise in advanced ovarian cancer surgery because I saw that this was the area where training, skill, dedication, and perseverance made the most difference.
In my clinical practice, I have extensive experience in the use of minimally invasive surgical techniques. Using this advanced technology helps us improve outcomes for patients with early-stage cancers of the ovaries, uterus, and cervix. When appropriate, I offer my patients newer treatment options, such as sentinel lymph node biopsy, fertility-preserving surgery, and robotic surgery, as well as panniculectomies (removal of excess fat from the lower abdomen). These techniques improve outcomes, both surgically and cosmetically, and ultimately help improve patient quality of life.
When patients with known or suspected cancers — especially those with advanced ovarian cancer — first come to see me, they are often concerned with removing the cancer as soon as possible. I reassure all my patients that, together, we will decide on the best treatment plan in the timeliest manner possible. When patients need surgery, we try to schedule their procedure as soon as possible from their initial consultation date. But we also take the time to make sure that we are pursuing the appropriate surgery, so as not to rush into a decision. I also remind my patients that we have a team of dedicated surgeons, medical oncologists, radiologists, pathologists, anesthesiologists, and nurses who are all committed to their care. As a result, we have some of the best surgical outcomes for advanced ovarian cancer in the world. Our patients’ quality and quantity of life is our top priority.
Over the past 25 years, I have dedicated much of my research to exploring ways to expand and improve our surgical management of ovarian, fallopian tube, and peritoneal cancers. I have published more than 100 papers on surgery for ovarian cancer, and I have been the principal investigator of many institutional and multicenter trials aimed at improving outcomes for patients with this disease. In addition, I, along with my colleagues at the University of California, Irvine, and UCLA, are working on the fourth edition of our textbook, Ovarian Cancer: Principles and Practice. I am the editor of two other textbooks, including Principles and Practice of Gynecologic Oncology, which is considered one of the leading textbooks in our field. I have given numerous major presentations about surgery for gynecologic cancers internationally, and I am passionate about collaborating with my colleagues around the world.
Some of our current clinical investigations at MSK include identifying ways to decrease the need for blood transfusions during surgery, decrease infections and stress on the immune system, and administer heated chemotherapy directly into the abdomen after the removal of cancerous tumors. I have also worked with international colleagues to establish clinical guidelines for determining who are appropriate candidates for second and third surgeries in cases of recurrent ovarian cancer. My goal is not only to improve the quality of life and long-term remission for patients with difficult cases of very advanced or recurrent disease, but also to offer hope where very little may have existed before.
In addition to my clinical and research activities, I have served on many national and international professional committees, including the American Board of Obstetrics and Gynecology, the Society of Memorial Gynecologic Oncologists, the Metropolitan Gynecologic Cancer Society, and the Gynecologic Cancer Task Force of the American Joint Committee on Cancer. For many years, I have been Director of the Society of Gynecologic Oncology’s annual postgraduate surgical courses, developed to keep gynecologic oncologists throughout the world up to date on the latest surgical treatments for patients with gynecologic cancers. I am also on the faculty of the University of California, Irvine, international course on cytoreductive surgery, as well as in the European School of Abdomino-Pelvic Surgery in Gynecologic Oncology, based in Italy. Our passionate mission is to improve the care and outcomes of patients with gynecologic cancers — not just in our own countries, but everywhere.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2012-2020)
- New York Times Super Doctors (2008-2016)
- New York Metro Area Top Doctors (2011-2016)
- America’s Top Doctors (2012-2016)
- America’s Top Doctors for Cancer (2012-2016)
- Newsweek’s America’s Top Doctors for Cancer (2015)
- Korean American Medical Association Physician Leader Award (2015)
- Cycle for Survival Award for Ovarian Cancer Research (2016)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Surgery for Ovarian Cancer: Principles and Practice. 3rd ed. Bristow RE, Karlan BY, Chi DS, eds. New York: Informa Healthcare; 2015.
Selected Book Chapters
“Cancer of the ovary, peritoneum, and fallopian tube.” Chi DS, Kauff ND. In: PRECIS: Oncology. 3rd ed. Danvers MA: American College of Obstetricians and Gynecologists; 2007: 88-100.
“Cervical cancer.” Chi DS, Perez CA, Kavanagh J. In: Cancer Management: A Multidisciplinary Approach. 11th ed. Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Norwalk, CT: UBM Medica; 2008: 465-496.
“Pelvic exenteration.” Levine DA, Bochner BH, Chi DS. In: Atlas of Procedures in Gynecologic Oncology. 2nd ed. Levine DA, Barakat RR, Abu-Rustum NR, eds. London: Informa Healthcare; 2008: 93-116.
“Extended pelvic resection.” Diaz JP, Boland PJ, Chi DS, Abu-Rustum NR. In: Atlas of Procedures in Gynecologic Oncology. 2nd ed. Levine DA, Barakat RR, Abu-Rusturn NR, eds. London: Informa Healthcare; 2008: 137-144.
“Hand-assisted laparoscopic splenectomy.” Diaz JP, Chi DS. In: Atlas of Procedures in Gynecologic Oncology. 2nd ed. Levine DA, Barakat RR, Abu-Rustum NR, eds. London: Informa Healthcare; 2008: 267-270.
“Surgical principles in gynecologic oncology.” Chi DS, Gallup DG, Bristow RE. In: Principles and Practice of Gynecologic Oncology. 5th ed. Barakat RR, Markman M, Randall ME, eds. Philadelphia: Lippincott, Williams & Wilkins; 2009: 269-287.
“Secondary cytoreductive surgery.” Bristow RE, Chi DS. In: Surgery for Ovarian Cancer: Principles and Practice. 2nd ed. Bristow RE, Karlan BY, Chi DS, eds. New York: Informa Healthcare; 2010: 218-234.
“Advanced cytoreductive surgery program development: building a cytoreductive team.” Zivanovic 0, Chi DS, Karlan BY. In: Surgery for Ovarian Cancer: Principles and Practice. 2nd ed. Bristow RE, Karlan BY, Chi DS, eds. New York: Informa Healthcare; 2010: 291-300.
“Video-assisted thoracic surgery.” Eitan R, Chi DS. In: Textbook of Gynaecological Oncology. 2nd ed. Ayhan A, Reed N, Gultekin M, eds. Ankara, Turkey: Gunes Publishing; 2011.
“Secondary cytoreduction in the treatment of recurrent ovarian cancer.” In: Textbook of Gynaecological Oncology. 2nd ed. Ayhan A, Reed N, Gultekin M, eds. Ankara, Turkey: Gunes Publishing; 2011.
Visit PubMed for a full listing of Dr. Chi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dennis S. Chi discloses the following relationships and financial interests:
Taylor & Francis Group
Intellectual Property Rights
Ownership / Equity Interests
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.